Alessandra Curioni-Fontecedro
Cantonal Hospital Fribourg / University of Fribourg · University Hospital, Zürich
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandra Curioni-Fontecedro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07158489 · Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCSwiss Cancer Institute · recruiting · NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) · study chair
- Ph2NCT04480372 · SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IISwiss Cancer Institute · completed · Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
- Ph3NCT02991482 · PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaETOP IBCSG Partners Foundation · completed · Pleural Mesothelioma Malignant Advanced · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:36 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.Lancet Respir Med · 2017159 citationsRCR 4.8
- First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.J Immunother Cancer · 202363 citationsRCR 4.2
- 51 citationsRCR 2.2
- Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.Eur J Cancer · 202418 citationsRCR 1.7
- 16 citationsRCR 0.4
- Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).Br J Cancer · 20198 citationsRCR 0.3
- Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.Lung Cancer · 20258 citationsRCR 1.6